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Abstract
Background: The prevalence of chronic kidney disease is on the rise globally and in sub-Saharan Africa. Due to its
“silent” nature, many patients often present with advanced disease. At this point options for care are often limited
to renal replacement therapies such as hemodialysis and kidney transplantation. In resource limited settings, these
options are associated with catastrophic expenditures and increased household poverty levels. Early palliative care
interventions, if shown to ensure comparable quality of life (QoL), can significantly mitigate this by focusing care on
comfort, symptom control and QoL rather than primarily on prolonging survival.
Methods: A mixed methods longitudinal study, recruiting patients with End Stage Renal Disease (ESRD) on
hemodialysis or conservative management and following them up over 12 months. The study aims are to: 1)
measure and compare the health-related quality of life (HRQoL) scores of patients with ESRD receiving hemodialysis
with those receiving conservative management, 2) measure and compare the palliative care needs and outcomes
of patients in the two groups, 3) explore the impact of treatment modality and demographic, socio-economic and
financial factors on QoL and palliative care needs and outcomes, 4) review patient survival over 12 months and 5)
explore the patients’ lived experiences. The Kidney Disease Quality Of Life Short Form version 1.3 (KDQOL-SF) will
be used to measure HRQoL; the African Palliative Care Association Palliative care Outcome Score (APCA POS) and
the Palliative care Outcome Score for renal symptoms (POS-S Renal) will be used to assess palliative care needs and
outcomes; and semi-structured in-depth interviews to explore the patients’ experiences of living with ESRD. Data
collection will be carried out at 0, 3, 6, 9 and 12 months.
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Discussion: To the best of our knowledge, no similar study has been conducted in sub-Saharan Africa. This will be
an important step towards raising awareness of patients’ need and preferences and the strengths and limitations of
available health care services for ESRD in resource limited settings.
Keywords: Quality of life [MeSH], Kidney failure, Chronic [MeSH], Palliative care [MeSH] renal Dialysis [MeSH],
Developing countries [MeSH], Mixed methods, Resource limited setting, Low and middle income countries, LMIC
Background
The global prevalence of Chronic Kidney Disease (CKD)
is estimated at 8–16% [1–3], with this patient population
being at the highest risk for progression to End Stage
Renal Disease (ESRD). The prevalence of CKD in sub-
Saharan Africa (SSA) at 12–23% [4–6] is higher than the
global average of 13.4% [3]. This may be explained by
the current burden of communicable diseases as well as
the growing pandemic of non-communicable diseases
such as diabetes and hypertension, which are the leading
causes of CKD worldwide. Prevalence of CKD increases
with age and as the aging population in low and middle
income countries increases, prevalence of CKD is pro-
jected to increase further [3, 4, 6, 7].
CKD places significant demands on health systems in
the form of medical consultations, medications, and
renal replacement therapies (RRT) such as hemodialysis
and kidney transplants. In addition to the lived experi-
ence of disease burden and direct health care costs,
CKD patients and their carers have to face costs which
often remain unacknowledged at the system level, such
as of transportation, accommodation in greater proxim-
ity to centres of care, and time spent away from
productive employment. A systematic review of the
worldwide access to RRT in 2010 estimated that 2·6
million people were receiving such therapy, yet almost
two to four times more, 4.9 to 9.7 million, were in need
of it without having access to it. Those estimates were
projected to mean that 2.3 million people might have
died prematurely due to lack of access to RRT. Num-
bers continue to rise, with the largest treatment gaps
occurring in low-income countries, particularly Asia
(1·907 million people needing but not receiving RRT;
conservative model) and Africa (432 000 people; con-
servative model) [8].
The World Health Organization (WHO) recognises
the improvement/ minimization of deterioration of a pa-
tient’s quality of life as a key outcome of any successful
disease management and ESRD is no exception [9].
ESRD has been shown to be associated with poor
Health-Related Quality of Life (HRQoL) in both devel-
oping and developed countries, for instance Kenya,
Guinea, India and the United Kingdom [8–11]. Factors
significantly associated with poor HRQoL included:
older age, higher symptom burden and comorbidities,
more physical pain and more physical and social limita-
tions [9]. In Malawi low household income (< $4000 per
year) was associated with lower scores on the mental
health component and low physical health scores were
found to discourage many patients from seeking treat-
ment, particularly if they were the bread winners in their
families [10].
The role of palliative care, an approach that aims to
improve quality of life, in ESRD has been recognized
and developed in USA, UK, Canada, Australia and most
developed countries [11–14]. It involves helping patients
to cope with their illness and choose care pathways (dia-
lysis vs. conservative care, withholding dialysis, making
advance care directives), and provides a multidisciplinary
holistic approach to care at the end of life [11, 15, 16].
Patients with ESRD, irrespective of their management
modality, have significant morbidity and mortality, with
one study showing an average of 10.5 symptoms in the
severely ill [15]. These patients have been shown to
benefit significantly from palliative care services [11, 17,
18]. In practice, however, palliative care is offered to pa-
tients on conservative management more often than it is
offered to patients on hemodialysis. Also, there are no
well-established palliative care pathways for such pa-
tients even in developed settings.
There is a scarcity of evidence on palliative care in
ESRD from developing countries and a significant vari-
ation in the models of palliative care delivery in ESRD in
developed countries.. This has made it difficult to for-
mulate guidelines for palliative care in ESRD in develop-
ing countries. This study therefore aims to bridge this
gap by contributing to the limited body of knowledge on
palliative care and HRQoL in ESRD patients in develop-
ing countries.
Methods/study design
This study is a doctoral project of the first author (PB)
funded by the Training Health Researchers into Voca-
tional Excellence (THRiVE) consortium in Uganda. It is
a mixed methods longitudinal study, with a 1-year follow
up. Quantitative (Part 1) and Qualitative (Part 2) arms of
the study will take place concurrently, both in terms of
data collection and analysis.
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Aims and objectives
The overall aim of the study is to improve our under-
standing of quality of life amongst patients with ESRD
receiving care in a resource limited setting – Mulago
National Referral Hospital in Uganda, and the implica-
tions this has for the provision of palliative care in
addition to standard nephrology care in resource limited
settings.
The objectives of the quantitative arm of the study are:
1 To measure the HRQoL scores of a sample of
patients with ESRD receiving care at Mulago
National Referral Hospital;
2 To compare the HRQoL scores of a sub-sample of
the above patients who are receiving hemodialysis
to the scores of a sub-sample of patients who are
on conservative management;
3 To elicit and compare the factors that influence the
HRQoL of those two sub-samples of patients;
4 To calculate the 12-month mortality rate of the full
sample of patients.
The objective of the qualitative arm of the study is:
1 To explore the lived experience of ESRD of the
recruited patients.
Longitudinal follow-up will be for 12 months, with
quantitative reviews every 3months and repeat qualita-
tive interviews every 6 months. In following up these pa-
tients we are assessing changes to their quality of life,
management modalities they are utilizing and number of
admissions as well as place of death for patients who die
during the course of follow up. Follow up will not in-
clude blood tests to examine serum biochemical changes
at every interaction.
Study site
Uganda is a sub-Saharan country located in East Africa
with an estimated population of 40 million [19]. Mulago
Hospital is the largest health care facility in the country
with a bed capacity of 1500. It is the main national refer-
ral hospital, meaning that the majority of the patients
seen have been referred from lower tier health care facil-
ities due to the complexity of the patient’s illness. All
adult medical inpatient and outpatient services are cur-
rently seen at the Kirrudu site, where all the data collec-
tion will take place other than in cases where interviews
are conducted, as per the patient’s preference for ex-
ample in their home .
Adult patients admitted to the medical wards come in
through the medical emergency ward or the outpatient
clinics. Patients with confirmed or suspected kidney dis-
ease are admitted to the nephrology ward which, on
average, provides care for 15–30 patients daily. The out-
patients’ clinic runs every Tuesday, with 5–10 new and
20–25 follow-up patients per week. The hemodialysis
unit, housed in the same building, operates 15 to 20
functional dialysis machines and runs two to three pa-
tient shifts daily, 6 days a week. It has 150–200 active
hemodialysis patients at any one point. The Unit being a
government run public facility requires patients to pay a
highly subsided cost for dialysis for only two sessions
per week but they have to pay the full amount if they
have to undergo a third session. From anecdotal evi-
dence patients with CKD in this setting are started on
hemodialysis by the attending nephrologist when they
develop features of the Uremic syndrome, volume over-
load, metabolic acidosis or hyperkalaemia all of which
are refractory to treatment. A decision to initiate or
withhold dialysis involves all relevant parties including
the carers, patient and healthcare workers agreeing to-
gether on a course of action. Often the main factor
leading to no dialysis and therefore conservative man-
agement is the lack of funds to pay for catheterization
and the hemodialysis procedure not because they are
very sick. Occasionally, especially in patients aged over
75 years, extensive co-morbidities may be a factor, but
this is not very common because the average population
age in our setting is 45.9 years.
Study approvals
Ethical approval was provided by the School of Medicine
Research and Ethics Committee of Makerere University
(#REC REF 2018–005). Administrative clearance to carry
out this study at Mulago National Referral Hospital was
given by the Hospital Administration following review
and approval by the Mulago Hospital Research and Eth-
ics Review Committee (MHREC 1543). The Uganda Na-
tional Council for Science and Technology (UNCST)
also reviewed and approved the study (HS 2573).
Study population
To be eligible for participation in the study, patients
must be aged 18 years and above with documented evi-
dence of ESRD defined as CKD stage V (estimated glom-
erular filtration rate of 15mls/min/1.73m2 or less
calculated using Cockcroft-Gault Formula). They should
be admitted on the nephrology inpatient ward or to be
attending the outpatient nephrology or hemodialysis
clinics. They should have decision making capacity to
enable them to give informed consent to take part in the
study, as well as adequate cognitive and linguistic com-
petence and levels of physical functioning to allow them
to complete a questionnaire and participate in an inter-
view without undue strain.
Patients will be excluded if they do not have access to
a mobile telephone: this may be a personal mobile phone
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or one belonging to a trusted friend or family member
who can easily access the patient and whose knowledge
of the patient’s condition and study participation is fully
acceptable to the patient.
Patients with acute kidney injury defined as an ele-
vated serum creatinine for a period of less than 3
months as well as patients who do not meet the above
criteria about decision making capacity, cognitive and
linguistic competence and levels of physical functioning
will also be excluded.
Participant recruitment
Patients meeting the inclusion criteria will be recruited
through non-probability consecutive sampling from the
nephrology inpatient ward, the general nephrology out-
patient clinic (once weekly - Tuesday) and the outpatient
hemodialysis unit (Monday-Saturday). We chose this re-
cruitment design because of the small overall patient
numbers and anecdotal evidence of high morbidity and
mortality amongst them. There is a significant probabil-
ity for a large number of unsuccessful recruitment at-
tempts due to the severity of the illness with which
patients present at the hospital. Significant drop-out
rates are also expected due to the high likelihood of pa-
tient deterioration post-recruitment or death during the
study period.
The recruitment will be conducted by two research as-
sistants, both of whom are health care assistants with
diploma level medical training. They will receive training
in patient identification and recruitment, data collection
methods and the ethical conduct of research from the
doctoral candidate and primary investigator (PB). The
research assistants, upon identifying an eligible patient,
will introduce themselves and explain the purpose and
processes of the study. They will take extra care to clar-
ify that the patient’s decision will in no way influence
the health care they receive and that, even if they decide
to take part, they are free to withdraw at any time. The
patient will be encouraged to ask questions about the
study and to take time to consider whether they might
be interested in participating. If the patient expresses an
interest to join the study, they will be asked to sign a
consent form and given an information sheet to keep.
Quantitative arm
Sample size estimation
The sample size needed to compare the mean HRQoL
values for the 2 patient groups (on hemodialysis vs. con-
servative management) was estimated as follows:
Calculating sample size to achieve adequate power;
comparison of two means






n = sample size per group.
z1 = 1.96 for error of 5% (95% confidence level).
z2 = 1. 64 for 95% power.
= 1.28 for 90% power.
= 0.84 for 80% power.
s = standard deviation for of the outcome in control
group.
μ2 - μ1 = minimum meaningful difference between
means of the intervention and control group [20].
The calculation used z2 at the 0.84 level for 80%
power, meaning we expect a sensitivity of 80% from our
study findings. We used as a reference for the calcula-
tions the study of HRQoL in kidney disease by Manava-
lan et al. conducted in another setting with likely
resource limitations, namely South India [21]. The study
used the Kidney Disease Quality Of Life-Short Form
(KDQOL-SF) Version 1.3, which is also one of the tools
to be used in this study (see Data collection and Table 1
below). Patients had chronic kidney disease, were from
an area of predominantly low social and economic sta-
tus, and were seen in a tertiary referral center. In view of
such similarities, the values of S = 13.4 (standard devi-
ation for the control group, taken to be conservative
management group) and μ2 - μ1 = 5.08 (the minimum
meaningful difference between means of the intervention
and control group, observed in the ‘Effects of kidney dis-
ease’ item under the kidney disease specific domain)
were taken from the Manavalan et el. study [9].
N ¼ 1:96þ 0:84ð Þ22 13:4ð Þ2 = 5:08ð Þ2
¼ 109 participants per group
Total participants ¼ 1092 ¼ 218
Delays in presentation to tertiary care facilities often
result in advanced disease at presentation and are related
to poor survival rates [24, 25]. Based on such evidence
and observations of the PI and three colleagues (two se-
nior hemodialysis nurses and a nephrologist), all of
whom members of the Mulago Hospital nephrology
team, we anticipated a high level of attrition, which we
set at 30%.
Adjustment for attrition: N1 = N / (1-q), [20].
where N1 is adjusted sample size, N is unadjusted sam-
ple size and q is the attrition rate
N1 ¼ 218= 1 − 0:3ð Þ ¼ 311
We also adjusted for unequal group sizes because
fewer patients, due to cost and accessibility challenges,
are able to undergo hemodialysis [26].
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Adjustment for unequal group sizes: N1 = N (1 + k) 2 /
4 k [20].
N1 is adjusted sample size, N is unadjusted sample
size, k is the ratio of the 2 groups = 1: 2
N1 ¼ 311 1þ 0:5ð Þ2 =40:5 ¼ 350
Thus, 117 (350/3) patients will be allocated to the
hemodialysis group and 233 (350* 2/3) to the conserva-
tive management group.
For each participant, data will be collected over a
period of 12 months or less if their condition deterio-
rates significantly or if they die.
Data collection
The data collection questionnaire will consist of the
tools described in Table 1.
The KDQOL-SF was developed by the RAND Corpor-
ation and is a public document available for use by any
interested parties [27]. It is among the mostly widely
used QoL instruments specific to end stage kidney dis-
ease and has been validated and used extensively in both
developed and developing countries [10, 21, 28, 29]. As
part of the current study, the tool has been translated
and adapted to reflect the specificities of Ugandan
culture.
The process of translation followed the guidelines pro-
vided by RAND Health Care [30] (Appendix B). The
translation was into one of the local languages, Luganda,
the most commonly spoken language in the central re-
gion of Uganda, where Mulago Hospital is located. A
team of three native Luganda speakers worked together
to translate the instrument into Luganda. Back transla-
tion into English was then done by a fourth native Lu-
ganda speaker, who is also a linguist. The tool was than
tested to assess face and content validity in one focus
group discussion involving nine health care workers and
in five individual interviews. Culturally, the tool was
adapted by substituting activities which are uncommon
in the local setting, such as vacuuming or bowling, with
far more typical ones, such as sweeping or mopping the
house.
The African Palliative Care Association – Palliative
care Outcome Scale (APCA POS), validated in Uganda
[22], contains 10 items, addressing the physical and psy-
chological symptoms, spiritual, practical and emotional
concerns, and psychosocial needs of the patient and
family. Answers to all questions are scored using
Likert scales from 0 to 5, with numerical and descrip-
tive labels. Questions 1–7 are directed at patients;
questions 8–10 are directed at family informal care-
givers and include a ‘Not applicable’ option for use
when the patient does not have an informal carer. It
is staff-completed, owing to varying levels of patient
and family literacy. Respondents indicate their an-
swers either verbally or using a hand scale (0 = closed
fist, 5 = all fingers open). Like in the KDQOL-SF, the
scoring of some items is reversed, meaning that best
status can be represented by both high and low
scores. This ensures that administration and response
formulation for each individual item are conducted
with due care and attention.
Table 1 Data collection tools
• Kidney Disease Quality Of Life-Short Form
(KDQOL-SF) Version 1.3
The KDQOL-SF questionnaire (version 1.3) is an internationally validated instrument for asses-
sing the HRQoL of ESRD patients (41) and hemodialysis patients (42, 43).
It consists of measures of general health and measures specific to ESRD organized in three
domains:
- Physical health Component Summary (PCS), 21 items;
- Mental health Component Summary (MCS), 15 items;
- Kidney Disease Component Summary (KDCS), 44 items.
A total score and domain-specific PCS, MCS and KDCS will be calculated for each patient and a
mean score calculated for each of the sub-samples.
Total scores above 50 (max 100) are considered to represent good levels of quality of life.
• Socio-demographic data Demographic data: age, sex and marital status
Socio-economic data: educational level and employment status
Financial data: (approximate) total yearly household income and expenditures on health care.
• The African Palliative Care Association Palliative
care Outcome Scale (APCA-POS)
The APCA-POS, validated in Uganda, assesses patient palliative care needs and outcomes of
care [22]. It contains 10 items, seven for the patient only and three for the family. The following
aspects of holistic end of life care are explored:
- Physical (pain and symptoms)
- Psychological (patient and family worries)
- Existential / Spiritual (worthiness of life, feeling at peace)
- Social (confidence in caring for the patient).
Each item is scored on a scale of 0 to 5.
• The Renal symptoms Palliative care Outcome
Score (POS-S Renal).
The POS-S Renal assesses palliative care needs and outcomes specifically in patients with kidney
disease [23]. It assesses how a patient feels across a range of symptoms specific to kidney fail-
ure (scale of 0 to 4). It also elicits which symptom a patient feels has affected them the most
and which has improved the most.
Bagasha et al. BMC Nephrology          (2020) 21:531 Page 5 of 13
The Palliative care Outcome Scale - Renal has been
extensively used to assess the palliative care needs and
outcomes specifically in patients with kidney disease [16,
23]. It assesses how a patient feels across a range of
symptoms specific to kidney failure (scale of 0 to 4), in-
cluding a Not at all option for patients not experiencing
a particular symptom. In addition, it elicits which symp-
tom a patient feels has affected them the most and
which has improved the most.
Together, the above three instruments will provide a
multi-factorial quantitative perspective on the patients’
quality of life. Associations will also be explored between
scores on each of the three questionnaires and the hy-
pothesized predictors of HRQoL, including management
modality and the parameters included in the set of
sociodemographic data to be collected (see Table 1).
A pilot study involving 38 study participants was carried
out in May 2018. It showed that patients preferred to have
the questionnaire administered to them by the research
assistants. The questionnaire will therefore be printed on
paper and the two research assistants will administer it to
the eligible patients at the various study sites: in the wait-
ing areas; in the hemodialysis unit while a patient is
undergoing dialysis; or at a patient’s bedside in the neph-
rology unit. The research assistants have been trained to
maintain consistency in the administration of the ques-
tionnaire, to help the patient understand the meaning of
the questions and offer support without influencing their
responses. The PI has observed the research assistants ad-
ministering the questionnaire during pilot data collection.
Meetings were also held to enable further standardization
of the process, e.g. to ensure that the intended meanings
of questions are uniformly understood. Based on the pilot,
it is expected that the questionnaire will take about 30
min to administer. More time may be allowed for breaks
depending on the participants’ needs. We anticipate ad-
ministering 10 questionnaires per day. This will be done
at 0, 3, 6, 9 and 12months (see Table 2).
Two phone calls will be made in between patient re-
views to ensure close contact and reduce loss to follow
up. The first will be made at 2 months after a review.
The second will be made 1 week before the next review
to agree time and venue which are most convenient to
the patient.
Qualitative arm
The goal of the qualitative aspect of the study is to ex-
plore the multidimensional lived experience of a sub-
sample of the recruited patients at three time points: 0,
6 and 12months. Dimensions of interest will be the
physical, psychological, social, spiritual and pragmatic/
daily living aspects of the patients’ experience and the
factors that influence them. The knowledge gained from
the qualitative arm will be used to complement,
augment, explain and potentially challenge evidence ob-
tained from the quantitative arm.
Data will be collected through semi-structured in-
terviews (see Table 3 for schedule). The interviews
will aim to cover six broad thematic areas, while
giving as much opportunity to participants to lead the
interview as possible. The probing questions will be
used mostly if the interviewee needs clarification of
the initial broad question for a theme. The overall
goal will be to give space to the interviewee to struc-
ture the conversation and prioritize issues to talk
about than to cover the variety of subtopics within a
theme, as articulated in the probes.
The same schedule will be used to guide the interviews
at the three time points. After the original interview, the
goal will be to achieve greater depth of understanding;
to capture changes over time, as the patient’s experience
with the illness grows; and to clarify points that have
remained opaque during previous interviews. Before the
6- and 12-month interviews, the participant’s latest tran-
script will be reviewed to identify potential areas of focus
for the upcoming interview.












Recruitment relative to inclusion/exclusion criteria X
Informed consent X X X X X
Demographic data X
Management modality patient is on X X X X X
KDQOL X X X X X
APCA POS X X X X X
POS-S Renal X X X X X
Qualitative arm
Patient interview X X X
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Table 3 Semi-structured interviews guide
Introductory remarks:
• Transitional and ice-breaking comments and questions: follow situational cues to help the patient feel comfortable and establish a con-
nection, e.g. ask about their trip to the hospital, their appointment today, etc.
• Thank the interviewee again for agreeing to talk to you.
• Confirm that their participation is entirely voluntary and that they can withdraw at any point without giving an explanation and without
any consequences for the health care they receive.
• Ask them to tell you if at any point they feel tired and want to stop to take a break.
• Tell them that there are no right or wrong answers and you want to understand what they think and feel, that it is about their
experiences and it doesn’t matter what anyone else tells them is right, true, good …, even if it is the doctor [add another authority –
e.g. husband, mother, etc. if you have indications that they may have a significant influence on the patient]. If appropriate, can make a
joke adding the President or somebody famous to that list of authorities.
• Try to use as much of the language they are using – e.g. the way they call ‘End Stage Renal Disease’.
1. You and your illness
Core question: Could you tell me about your kidney disease? For instance, how and when you developed it and if it has changed your life or not?
Possible probes if interviewee asks for further guidance [though first try to paraphrase and reassure that any way they understand it is good] or if their
answer has been brief [again, first try to leave open – Anything else?]:
-When were you told that you have kidney disease?
-Where was that?
-What made you go to the doctor/ hospital?
-What did you know about kidney disease at the time?
-What do you think might have caused your kidney disease?
-What treatment are you currently receiving?
-Has kidney disease changed your life in some big ways?
-What do you feel is your biggest challenge about living with it?
2. Physical Health
Core question: Can you tell me how you’ve been feeling physically over the past 6 months? What do you feel in your body?
Possible probes if interviewee asks for further guidance [though first try to paraphrase and reassure that any way they understand it is good] or if their
answer has been brief [again, first try to leave open – Anything else?]:
-What physical ailments have you been having?
-Which ones have disturbed you the most? In what ways?
-Is the health care you are receiving helping enough with those ailments? Can you tell me a bit more? What is helping? What is not helping? What is
good about it? What is not that good?
-How many pills do you take in a day? How does it feel?
-Are they too many? Difficult to swallow? Expensive to buy?
-Do you feel they help enough? Or do they help for some things but make others worse?
-Do you sometimes skip some doses?
-How often do you come to the hospital?
-How far do you live? How far is it for you to travel? Does it make it difficult to come?
-What do you think about the care you are getting here at the hospital?
-Can you give me some examples of both when it was good and bad, or not so good?
3. Daily lif
Core question: How has kidney disease changed what you can do in your everyday life? The normal things that you do from when you wake up in
the morning to when you go to sleep at night?
Possible probes [again, use only after first opening space for the unguided understanding of the interviewee]:
Eating and drinking
-How is your appetite?
-Did you change the food you are eating? How are you finding the changes?
-Do you miss some of the things you shouldn’t eat? How do you like the ‘new’ foods?
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Table 3 Semi-structured interviews guide (Continued)
-Is it difficult to find some of those foods?
-What about the things you are drinking?
Movement, daily tasks and work
-Are there things that are more difficult to do because you feel weaker?
-What about daily tasks and self-care? E.g. bathing, eating, turning in bed, transferring from bed to chair? What about vigorous activity, like fetching
water?
-What about working to earn money?
-Going out of the house and visiting friends and family?
Sleep
-Do you have trouble sleeping?
-What makes it worse? What makes it better?
-What do you think about when you can’t fall asleep?
-How do you feel if you haven’t slept well?
Family
-Who in your family knows about your illness? How much have you told them?
-How did the conversation go?
-What were their reactions?
-How are they supporting you in living with the illness and taking care of your health?
-In what ways are they helping? E.g. helping at home, visiting you in the hospital, looking after you in the hospital, bringing you food, paying some
of your bills … .
-My next questions may feel too personal, remember it’s entirely up to you how much or little (or not at all) you say, but how has the illness affected
your relationship with your spouse or partner? Or if you are not in a relationship, your plans for one?
- Has your illness affected your sexual relations?
-Going back to the support you are getting from your family as a whole, can you give me some examples of when it felt good and when it didn’t?
Money
-Do you have a job or some other steady source of income?
-How much money do you spend on your health care in a month? Medication, consultation fees for doctors, transport, food while in the hospital,
rent, etc.?
-How much of your monthly income is that?
-How do you manage those expenditures?
-Have you needed to borrow money?
-Does spending on your health care mean others in the family can’t get what they need or have to wait for it longer? What do they say? How do
you feel? [Might need to close topic and move on with a compassionate comment that it’s a big and difficult topic.]
4. Psychological Health
Core question: How has kidney disease affected how you feel? About yourself, about life in general? Has your usual mood changed?
Possible probes [again, use only after first opening space for their unguided understanding]:
- Do you feel that this disease is stressing you out? In what ways?
-Do you feel like a burden to your family? Can you tell me a bit more?
-Do you worry about your future? What do you most worry about?
-Has this changed how you plan things?
-Do you ever think about a time when you are no longer in this world?
-If yes, what are your thoughts on this?
-Have you made a will or discussed it with anyone?
-If you don’t want to think about a future when you are no longer in the world, can you tell me very briefly why, only so that I may understand, not
because I want to make you think about it.
-Has your illness brought about anything positive? Do you sometimes feel good about it?
5. Social Health
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Patient sampling and recruitment
Interviewees will be recruited from amongst patients
who have already agreed to participate in part 1 of the
study, by asking them whether they would like to partici-
pate in an interview too or only respond to the question-
naire. Selected participants will have to be physically and
cognitively able to participate in a 30–45min in-depth
interview and to have consented to the interview and the
audio recording. We will use purposive maximum vari-
ation sampling, with variation based on age, sex,
duration of illness, duration on treatment modality,
estimated glomerular filtration rate at baseline, other
morbidity, and HRQoL scores at baseline.
Once identified as fitting the above criteria, partici-
pants will be approached again by the research assistant
who had administered the quantitative questionnaire
and asked for a time and place convenient to interview
them.
Sample size estimation
The final sample size will be determined by the point at
which we achieve data saturation, i.e. no new informa-
tion or theme is identified during progressive interviews
[31]. Based on comparable research, we estimate that
data saturation will be achieved after 25–30 maximum
variation patient interviews [32].
Data collection
The interviews will be conducted face-to-face by the
principle investigator assisted by one research assistant
with training in qualitative interviews.
Field notes will be taken during and after the inter-
views to provide context for the data analysis and inform
subsequent interviews. Interviews will be conducted in
Luganda, English or Runyankole, depending on patient
preference. The interviews will be audio-recorded, with
patient permission. Interviews conducted in English will
Table 3 Semi-structured interviews guide (Continued)
Core question: Can you tell me how your illness has affected your relationships with other people? We spoke of your immediate family (and can
come back to it), but perhaps we can talk more about your friends, neighbours, workmates, maybe other patients or even strangers?
Possible probes [again, use only after first opening space for their unguided understanding]:
-Do people other than your family help you in living with your illness or taking care of your health? E.g. neighbours, friends, workmates?
-How are they trying to help you?
-How do you feel about that? In what ways is it good? In what ways it isn’t?
-Have you lost touch with some people because of your illness? How did it happen?
-Do some organizations, such as NGOs, provide support? In what ways?
-Do you sometimes feel lonely? Or too different from others?
6. Spiritual Health
Core question: It may feel a very big, serious question, and it’s entirely up to you if you want to think and talk about such things, but can you tell
me what helps you cope with your illness or what gives you strength when facing a difficult illness such as the one you are going through?
Possible probes [again, use only after first opening space for their unguided understanding]:
-Do you believe in God or a higher power?
-How has your illness affected your faith and your sense that life has a meaning?
-Has your faith helped you accept and live a good life in spite of your illness? Can you tell me of such times?
-Or has the opposite happened, you started losing faith because of your disease? Can you tell me of such times?
-What gives you hope? Can you tell me of times when you had high hopes about your health?
-What makes you lose hope about your health? Can you tell me of situations when that’s happened?
-Are there any religious practices which help you cope with your illness?
7. Wrapping up
• Thank you for your time and contribution to this study, we are just wrapping up now. I would like to know, given what you have been through so
far, what advice would you give to a fellow patient?
• What about health care providers? How can they help patients better?
• How about the Government and Ministry of Health? How can they contribute to improving your health as a kidney disease patient?
• What information would you like to have about your health in general and kidney disease?
• Is there anything else you’d like to tell me?
• Is there anything else you’d like to ask me?
Thank you so much for your time and participation.
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be transcribed verbatim. Interviews in the local dialects
will be translated during transcription by study adminis-
trative staff highly competent in both the native
language and English. These translations will then be
checked by a native speaker of each language.
We expect to recruit 1–2 interviewees a week. Repeat
interviews will be conducted at 6 and 12 months from
the first interview.
Data management and storage
Questionnaire data will be entered into EpiData Ver. 3.1
[33] after data cleaning. Interviews will be audio-
recorded on a password-protected recorder, downloaded
onto a password-protected laptop and deleted from the
recorder at the end of each day. Printouts of anonymized
interview transcripts will be stored securely in a locked
cupboard. Physical data will be safely destroyed 5 years
after the end of the study.
Analysis plan
Quantitative analysis
Quantitative data will be analysed in STATA version
12.0 [34].
Primary outcomes
For objective one; overall scores will be calculated for
each participant for the KDQOL-SF 1.3 using the man-
ual for use and scoring provided by Hays et al. [27]. In-
dividual scores will then be computed into means and
then categorised into high and low scores (respectively >
and < 50/100). Mean scores for each of the three do-
mains will also be calculated and categorised (physical,
mental and kidney disease specific, respectively > 50
and < 50% of the sub-scale maximum score; decision on
treating mid-points will be taken in light of their
frequency).
For objectives two and three; participants will be di-
vided into the HD and non-HD groups based on the
management they are receiving at the time of assessment
and scores categorised into these groups. Exploratory
analyses will be used to compare the mean at 3 months
between categories of categorical variables (such as
gender, marital status, comorbidity) using ANCOVA
adjusting for baseline scores. The association between
KDQOL-SF scores and other continuous variables will
be investigated using simple linear regression with
KDQOL-SF scores at 0 months as the dependent vari-
able. Multiple linear regressions will be used to explore
the relationship between KDQOL-SF, APCA POS and
POS-S Renal scores on the one hand and, on the other,
management modality, age, sex, marital status, educa-
tional level, employment status, total yearly household
income and expenditures on health care. Statistical sig-
nificance will be assumed for P-values < 0.05. Biases due
to repeated measurements will be addressed during data
collection by consistency and training of research
assistants but also during analysis by using Generalized
estimated equations (GEEs) and as required mixed –ef-
fects models.
For objective four: Descriptive summaries of the pa-
tient socio-demographic question-naire data at 0,3,6,9
and 12months will be tabulated and presented graphic-
ally where appropriate. The number (%) of deaths at 3,
6, 9 and 12months will be tabulated. Time to death data
will be investigated using Kaplan Meier curves. The log
rank test statistic will be used to compare categorical
variables and Cox proportional hazards model for con-
tinuous variables where appropriate.
Qualitative analysis
Qualitative data will be analysed using NVivo 12 plus
[35]. Interview transcripts and field notes will be read
and reread several times with the intent of finding pat-
terns and relationships, revealing deeper meanings and
understanding participants’ stories. First cycle codes will
be developed utilizing principles of open coding. Codes
will describe sections of texts of various length forming
a thematic unit. A second cycle of coding will then fol-
low, involving constant comparison between new and
existing codes and the interview excerpts which under-
pin them. This will lead to the formation of higher level
categories and finally broad themes. Issues emerging
from each interview will contribute to the questions
asked alongside the existing interview guide at subse-
quent interviews until data saturation is reached [36].
Four researchers are involved in the coding of qualita-
tive data. Two of these have PhDs and between them
over five publications from qualitative studies they have
been involved in. One is a PhD candidate who has have
training in qualitative methodology and who will be
doing the bulk of the work under the supervision of the
more senior colleagues. The fourth is a palliative care
nurse with over 10 years experience in patient care and
qualitative data collection and analysis. All the four have
reviewed at least two transcriptions and agreed on the
codes developed.
Ethical considerations
To obtain informed consent a detailed explanation of
the study aims, procedures, benefits and potential harm,
and the intension to disseminate information gathered
through publication and at local and international meet-
ings of all relevant stakeholders, will be provided to the
patients. Patients will be assured of their freedom to
withdraw from the study whenever they wish.
To maintain patient confidentiality, each study partici-
pant will be assigned a patient identification code. Only
the patient identification code will be used in the final
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data base. Each interview participant will be assigned a
pseudonym in the transcripts. The key linking patient
identification codes with patient names and/or other
identifying data (e.g. for the purposes of checking
mortality data) will be accessible only to the PI on a
password protected computer.
We anticipate the following ethical dilemmas to arise
and intend to use the following approaches to handle
them:
a Choice of treatment (dialysis vs. conservative
management), especially as kidney function
declines: Patients will be fully counselled about
their options and their decision will not be
influenced by the study.
b Availability of specialist care and appropriate
referrals not being possible for patients, especially
those with financial limitations: This is an ethical
dilemma which the team experiences on a regular
basis. It has been one of the key motivations for
conducting the study and collecting evidence that
compares quality of life and outcomes for patients
on hemodialysis and conservative management
(with the latter demanding less specialist
involvement and much less financial resource on
the part of patients and families).
c Patients whose condition deteriorates as the study
progress: We will ask for informed consent from
the patient at each visit. Baseline consent will be
both verbal and written and only verbal at
subsequent interactions. Patients will be assured at
all times that they can withdraw from the study at
any point if they so wish.
Patient switch over
The study does not involve switching over of patients
and this remains a decision of the hospital care teams.
However, it is likely that some patients will choose to
have their treatment changed during the course of the
study. The data of patients who switch over from one
arm to another will be analysed based on the arm they
were in at the time of data collection. If these patients
form a large enough group, further, more focused
analysis will also be conducted.
Discussion
Global standards of care for patients with chronic kidney
disease aim to modify disease progression and holistic-
ally improve quality of life, including through the early
integration of palliative care. High quality and multi-
modal evidence around quality of life in this patient
group can help identify areas of greatest need and poten-
tial for improvements of care provision as well as serve
as a baseline against which to evaluate improvement
initiatives.
This study will utilize a mixed methods longitudinal
design to explore the quality of life, palliative care needs
and outcomes, lived experience and mortality of patients
receiving treatment for ESRD in a resource limited set-
ting. It will compare patients undergoing conservative
management and hemodialysis management following
them up for 12 months. It will generate local evidence
that is, in many respects, unique for Uganda. To our
knowledge, this is the first study which utilizes a mixed
methods approach to explore HRQoL for patients in
Uganda. It is also the first to collect qualitative data on
chronic kidney disease patients in Uganda and on their
palliative care needs and outcomes. Furthermore, it is
the first study in the country to follow up a cohort of
kidney disease patients to assess their 12-month survival.
Such evidence can be used to inform the development
of interventions and support infrastructure for patients
and their informal carers, training for health care
workers, and information briefs for policy makers, as
part of synergistic efforts to increase the quality of life of
patients with End Stage Kidney Disease.
A main limitation of this study is the use of conveni-
ence sampling and one site for data collection. This will
constrain the generalizability of findings. However, the
study site is the largest renal center in Uganda, which re-
ceives referrals from all regions of the country, including
three neighboring countries. A set of additional limita-
tions concerns issues around languages and mobile
phone access. The study questionnaire has been trans-
lated in only one of the local languages, be it the most
widely spoken in the region. A proportion of the in-
depth interviews will also be translated from local lan-
guages into English. While translations will be carried
out by bilingual translators for each of the local lan-
guages to ensure the highest possible quality, there is a
possibility that subtle differences and nuance, arising
from differences in both the culture and language, are
lost. Importantly, the study PI is a core member of the
hospital nephrology team and much of the data collec-
tion is conducted in spaces where patients are receiving
care. In spite of the careful explanations given by the re-
search team, patients may still refrain from voicing con-
cerns about the care they are receiving. Participants may
also exhibit the Hawthorne effect, whereby the very par-
ticipation in the study, with the significant attention and
opportunities for sharing their experiences they are
given, improves their overall experience of ESRD.
Concerning mobile phone access, surveys by the
National Information and Technology Authority (NITA)
have demonstrated that 70.9% of individuals surveyed
(2400 individuals sampled from all regions in the coun-
try) owned a mobile phone [37]. With no better options
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available for tracing and following participants we con-
sidered this to be an acceptable level of coverage. To
minimize this limitation we included participants who
did not own mobile phones but they had to have con-
tacts of close relatives or friends with phone contacts
and therefore enable us to get in touch with them.
While such limitations need to be taken seriously in
interpreting the resulting evidence and improved upon
in further research, this is, nonetheless, a unique study
for End Stage Renal Disease patients in Uganda with im-
portant implications for the health care they receive. It is
also an important step to raise awareness of the
strengths and limitations of health care services in the
country for what is, currently, its 5th most common
cause of death.
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